Trial Profile
A Long Term, Multicenter, Non-interventional, Observational Study Monitoring Long-term Safety and Effectiveness of Fingolimod 0.5 mg in Patients With Multiple Sclerosis Who Have Participated in the Fingolimod Clinical Development Program.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms LONGTERMS
- Sponsors Novartis
- 19 Jun 2018 Results assessing MRI outcomes presented at the 4th Congress of the European Academy of Neurology.
- 19 Dec 2017 Results of a substudy (n=13) assessing seminal concentration of fingolimod and fingolimod-phosphate in multiple sclerosis male patients from TRANSFORMS extension (NCT00340834) or the LONGTERMS study (NCT01281657), published in the Clinical Pharmacology in Drug Development Journal.
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.